Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8521392 | 1.00 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8750818 | 0.88 | HTR3E (0.42) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8750821 | 0.88 | HTR3E (0.42) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8750836 | 0.87 | HTR3E (0.41) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8750833 | 0.87 | HTR3E (0.41) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8750758 | 0.86 | FAAH (0.42) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8750771 | 0.86 | HTR3E (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8750773 | 0.86 | HTR3E (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8750752 | 0.86 | FAAH (0.42) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8750776 | 0.85 | HTR3E (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0956866-A1 | DRUGS FOR AMELIORATING OPHTHALMIC CIRCULATORY DISTURBANCE | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-11-17 | — | — | EP | claimed |
| EP-0634400-B1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BREWERY (JP) | 1997-04-02 | — | — | EP | claimed |
| US-5508293-A | TREATING HYPERTENSION, ANGINA PECTORIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1996-04-16 | — | — | US | claimed |
| EP-0634400-A1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BEER KABUSHIKI KAISHA (JP) | 1995-01-18 | — | — | EP | claimed |
| JP-8165239-A | — | — | None | — | — | JP | disclosed |
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-0956866-A1 | DRUGS FOR AMELIORATING OPHTHALMIC CIRCULATORY DISTURBANCE | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998035673-A1 | DRUGS FOR RELIEVING PERIPHERAL CIRCULATION DISORDER | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-20 | — | — | WO | disclosed |
| EP-0634400-B1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BREWERY (JP) | 1997-04-02 | — | — | EP | disclosed |
| JP-H08165239-A | ANTI-ARTERIOSCLEROTIC AGENT | KIRIN BREWERY CO LTD | 1996-06-25 | — | — | JP | disclosed |
| US-5508293-A | TREATING HYPERTENSION, ANGINA PECTORIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1996-04-16 | — | — | US | disclosed |
| EP-0634400-A1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BEER KABUSHIKI KAISHA (JP) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | HTR3E 1829/4885HTR3B 2110/4885HTR3A 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.